Rajendra Pradhan

1.0k total citations
33 papers, 795 citations indexed

About

Rajendra Pradhan is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Rajendra Pradhan has authored 33 papers receiving a total of 795 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pulmonary and Respiratory Medicine, 9 papers in Oncology and 7 papers in Molecular Biology. Recurrent topics in Rajendra Pradhan's work include Lung Cancer Treatments and Mutations (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Parathyroid Disorders and Treatments (3 papers). Rajendra Pradhan is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Parathyroid Disorders and Treatments (3 papers). Rajendra Pradhan collaborates with scholars based in United States, United Kingdom and Canada. Rajendra Pradhan's co-authors include Scott T. Rottinghaus, Rasha Aguzzi, Lily Wong Lee Lee, Hubert Schrezenmeier, Viviani Pessôa, Flore Sicre de Fontbrune, Wolfgang Füreder, Sandra Fátima Menosi Gualandro, Jong Wook Lee and В. В. Птушкин and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Rajendra Pradhan

32 papers receiving 773 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Rajendra Pradhan United States 14 248 210 200 131 121 33 795
Sonja Mandl–Weber Germany 16 77 0.3× 98 0.5× 511 2.6× 225 1.7× 97 0.8× 26 921
Kelly J. Norsworthy United States 13 137 0.6× 89 0.4× 449 2.2× 319 2.4× 69 0.6× 42 1.0k
Rastilav Bahleda France 18 153 0.6× 126 0.6× 514 2.6× 586 4.5× 434 3.6× 66 1.2k
Marie‐Hélène Schlageter France 19 93 0.4× 46 0.2× 342 1.7× 421 3.2× 106 0.9× 39 1.4k
Anita van Esch Netherlands 16 245 1.0× 113 0.5× 268 1.3× 693 5.3× 369 3.0× 16 1.3k
L. Jonathan Zwi New Zealand 15 65 0.3× 52 0.2× 314 1.6× 335 2.6× 108 0.9× 31 867
Andrija Bogdanović Serbia 17 162 0.7× 28 0.1× 294 1.5× 141 1.1× 55 0.5× 96 894
Donald C. Moore United States 13 90 0.4× 14 0.1× 206 1.0× 276 2.1× 141 1.2× 80 750
E Bastida Spain 21 124 0.5× 27 0.1× 352 1.8× 229 1.7× 190 1.6× 62 1.3k
Daphne Williams United States 14 30 0.1× 31 0.1× 235 1.2× 211 1.6× 104 0.9× 30 830

Countries citing papers authored by Rajendra Pradhan

Since Specialization
Citations

This map shows the geographic impact of Rajendra Pradhan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajendra Pradhan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajendra Pradhan more than expected).

Fields of papers citing papers by Rajendra Pradhan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rajendra Pradhan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajendra Pradhan. The network helps show where Rajendra Pradhan may publish in the future.

Co-authorship network of co-authors of Rajendra Pradhan

This figure shows the co-authorship network connecting the top 25 collaborators of Rajendra Pradhan. A scholar is included among the top collaborators of Rajendra Pradhan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rajendra Pradhan. Rajendra Pradhan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Mishra, Anjali, et al.. (2019). Edaravone: A New Hope for Patients with Amyotrophic Lateral Sclerosis. SHILAP Revista de lepidopterología. 16(3). 157–160. 1 indexed citations
2.
Lee, Jong Wook, Flore Sicre de Fontbrune, Lily Wong Lee Lee, et al.. (2018). Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study. Blood. 133(6). 530–539. 264 indexed citations
3.
Mostafa, Nael M., Balakrishna Hosmane, Lois Larsen, et al.. (2014). Pharmacokinetic and Exposure–Response Analyses of Leuprolide Following Administration of Leuprolide Acetate 3-Month Depot Formulations to Children with Central Precocious Puberty. Clinical Drug Investigation. 34(7). 441–448. 3 indexed citations
4.
Chiu, Yi‐Lin, Dawn M. Carlson, Rajendra Pradhan, & Justin L. Ricker. (2013). Exposure-Response (Safety) Analysis to Identify Linifanib Dose for a Phase III Study in Patients With Hepatocellular Carcinoma. Clinical Therapeutics. 35(11). 1770–1777. 11 indexed citations
5.
Wang, Eunice S., Karen Yee, Liang Piu Koh, et al.. (2012). Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia. Leukemia & lymphoma. 53(8). 1543–1551. 18 indexed citations
6.
Asahina, Hajime, Yosuke Tamura, Hiroshi Nokihara, et al.. (2012). An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemotherapy and Pharmacology. 69(6). 1477–1486. 19 indexed citations
7.
Tannir, Nizar M., Christian Kollmannsberger, Marc S. Ernstoff, et al.. (2011). Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. European Journal of Cancer. 47(18). 2706–2714. 24 indexed citations
8.
Goss, Glenwood, Ravi Salgia, Benjamin Besse, et al.. (2011). Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 6(8). 1418–1425. 54 indexed citations
9.
Noertersheuser, Peter, Rajendra Pradhan, Cheri E. Klein, et al.. (2011). Exposure—Clinical Response Analysis of Paricalcitol in Patients With Chronic Kidney Disease (Stage 5) on Hemodialysis or Peritoneal Dialysis. The Journal of Clinical Pharmacology. 52(8). 1162–1173.
10.
Zhu, Tong, et al.. (2010). Comparison of the Gastrointestinal Absorption and Bioavailability of Fenofibrate and Fenofibric Acid in Humans. The Journal of Clinical Pharmacology. 50(8). 914–921. 46 indexed citations
11.
Soo, Ross A., Septian Hartono, Choon Hua Thng, et al.. (2009). Phase I and Biomarker Study of ABT-869, a Multiple Receptor Tyrosine Kinase Inhibitor, in Patients With Refractory Solid Malignancies. Journal of Clinical Oncology. 27(28). 4718–4726. 72 indexed citations
12.
Gupta, Neeraj, et al.. (2009). Abstract B53: Assessment of the effect of food on the oral bioavailability and assessment of diurnal variation in the pharmacokinetics of linifanib. Molecular Cancer Therapeutics. 8(12_Supplement). B53–B53. 6 indexed citations
13.
Zhu, Tong, Walid M. Awni, Balakrishna Hosmane, et al.. (2008). ABT‐335, the Choline Salt of Fenofibric Acid, Does Not Have a Clinically Significant Pharmacokinetic Interaction With Rosuvastatin in Humans. The Journal of Clinical Pharmacology. 49(1). 63–71. 26 indexed citations
14.
Häkkinen, Sari, et al.. (2007). Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men. European Journal of Pharmaceutical Sciences. 32(4-5). 271–277. 17 indexed citations
15.
Ross, Edward A., Jin Tian, Hanna E. Abboud, et al.. (2007). Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Patients on Hemodialysis or Peritoneal Dialysis. American Journal of Nephrology. 28(1). 97–106. 52 indexed citations
16.
Palaparthy, Rameshraja, Rajendra Pradhan, Matthew J. Rieser, et al.. (2006). Effect of omeprazole on the pharmacokinetics of paricalcitol in healthy subjects. Biopharmaceutics & Drug Disposition. 28(2). 65–71. 4 indexed citations
17.
Abboud, Hanna E., Daniel W. Coyne, Michael S. Anger, et al.. (2006). A Comparison of Dosing Regimens of Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in CKD Stages 3 and 4. American Journal of Nephrology. 26(1). 105–114. 20 indexed citations
18.
Palaparthy, Rameshraja, Rajendra Pradhan, Qiang Wang, et al.. (2005). Pharmacokinetics and Safety of ABT-578, a Sirolimus (Rapamycin) Analogue, after Single Intravenous Bolus Injection in Healthy Male Volunteers. Clinical Drug Investigation. 25(8). 491–498. 8 indexed citations
19.
Karyekar, Chetan S., Rajendra Pradhan, Qin Ji, et al.. (2005). A Phase I Multiple‐Dose Escalation Study Characterizing Pharmacokinetics and Safety of ABT‐578 in Healthy Subjects. The Journal of Clinical Pharmacology. 45(8). 910–918. 10 indexed citations
20.
Pradhan, Rajendra, et al.. (1994). Formulation and in vitro release study on poly (dl-lactide) microspheres containing hydrophilic compounds: glycine homopeptides. Journal of Controlled Release. 30(2). 143–154. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sonja Mandl–Weber Breakdown of academic impact, for papers by Kelly J. Norsworthy Breakdown of academic impact, for papers by Rastilav Bahleda Breakdown of academic impact, for papers by Marie‐Hélène Schlageter Breakdown of academic impact, for papers by Anita van Esch Breakdown of academic impact, for papers by L. Jonathan Zwi Breakdown of academic impact, for papers by Andrija Bogdanović Breakdown of academic impact, for papers by Donald C. Moore Breakdown of academic impact, for papers by E Bastida Breakdown of academic impact, for papers by Daphne Williams
Rankless by CCL
2026